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Genome-wide association studies (GWAS) of urinary bladder cancer (UBC) have yielded common variants at 12 
loci that associate with risk  of the  disease. We report here the  results of a GWAS of UBC including 1670 UBC 
cases and 90 180 controls, followed by replication analysis in additional 5266 UBC cases and 10 456 controls. 
We tested a dataset containing 34.2 million variants, generated by imputation based on whole-genome sequen- 
cing of 2230 Icelanders. Several correlated variants at 20p12, represented by rs62185668, show genome-wide 
significant association with  UBC after combining discovery and replication results (OR 5 1.19, P 5 1.5 3 
10
211  
for rs62185668-A, minor allele frequency 5 23.6%). The variants are  located in a non-coding region ap- 
proximately 300 kb upstream from  the  JAG1  gene, an important component of the  Notch signaling pathways 
that may  be  oncogenic or tumor suppressive in several forms of cancer. Our  results add to the  growing 
number of UBC risk variants discovered through GWAS. 
 
 
 
INTRODUCTION 
 
Worldwide,  almost  400 000  individuals  are  diagnosed  with 
urinary bladder cancer (UBC) and .150 000 patients die from 
the disease every year (1,2). In the United States, UBC is the 
5th most common type of cancer with an estimated 72 500 new 
cases diagnosed and 15 200 deaths in 2013 (3). The male to 
female ratio of UBC is 3 : 1. Although in vitro studies and animal 
models support an essential role for the androgen receptor in 
UBC risk and progression, this gender difference has been larg- 
ely attributed to historical differences in tobacco smoking and 
occupational exposure to aromatic and heterocyclic amines, 
the most important risk factors for UBC. 
In addition to smoking and occupational exposures, genetic 
factors play a role in UBC risk. Population-based studies show 
that the risk of UBC is almost 2-fold the population average 
for the first-degree relatives of UBC patients (4,5) and the risk 
is even higher for relatives of young probands (4 – 6). Families 
with many cases of UBC are rare and segregation analyses 
suggest that the ‘no major gene’ model is the best one to describe 
the occurrence of UBC in these families (7). Taken together, 
these studies suggest that the genetic UBC risk may be largely 
conferred by many variants of moderate-to-low effect. Early 
genetic studies that focused on variants in carcinogen- 
metabolizing genes, strongly suggested that NAT2 slow acetyla- 
tor and GSTM1 null genotypes increase UBC risk (8). In addition, 
genome-wide association studies (GWAS) have yielded 12 UBC 
risk loci in populations of European ancestry (9 – 15). All the var- 
iants reported are common with risk allele frequencies .19% and 
exert a relatively weak effect on UBC risk (allelic odds ratios 
(ORs) ,1.24). 
In this study, we searched for additional variants that affect 
UBC risk in Iceland by performing GWAS on sequence variants 
identified through whole-genome sequencing of Icelanders and 
with follow-up of selected variants in .5000 UBC cases and 
10 000 controls from 11 European populations. 
 
 
RESULTS 
 
To search for sequence variants that associate with UBC, we 
performed a GWAS using information from the Icelandic 
Cancer Registry (ICR) on all UBC diagnoses in Iceland since 
1955 and sequence variants identified through whole-genome 
sequencing of Icelanders. At the beginning of this study, 2230 
Icelanders, including 22 UBC cases, had been whole-genome 
sequenced   to   an   average   sequencing   depth   of   22×.
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Approximately 34.2 million SNPs and small INDELs were iden- 
tified in this effort and, using imputation assisted by long-range 
phased haplotypes, the genotype probabilities of all the sequence 
variants were estimated for 826 UBC cases genotyped with Illu- 
mina chips and for additional 844 UBC cases who are close rela- 
tives of chip-typed individuals (16 – 18). The sequences of these 
1670 UBC cases were compared with the sequences of 90 180 
controls matched on genotype informativeness (see Materials 
and Methods). In this analysis, the marker showing the strongest 
association  with  UBC  was  the  previously  reported  SNP 
rs10094872-T on 8q24.2 (P ¼ 1.7 × 1027,  OR ¼ 1.26) (13). 
The variants reported to associate with UBC at 2q37.1, 3q26.2, 
3q28, 4p16, 5p15.3, 8p22, 8q24.21, 8q24.3, 11p15.5, 18q12.3, 
19q12 and 22q13.1 all showed effect in the reported direction 
with  P-values  ranging  from  0.06  to  1.7 × 1027   except  for 
rs10936599 at  3q26.2  (P ¼ 0.68)  and  rs8102137  at  19q12 
(P ¼ 0.21)  (Supplementary  Material,  Table  S1).  Since  our 
dataset allows testing of variants, both common and rare, that 
were previously not covered by HapMap or commercial chips, 
we scrutinized previously reported GWAS loci for variants 
representing the association better than the reported SNPs or 
representing additional independent signals. At three of the 
loci, we observed variants that have either slightly stronger asso- 
ciation in our data than the reported variants or coding variants 
that could potentially explain the observed association (Supple- 
mentary Material, Table S1). However, at none of the loci did we 
find evidence that the associated variants are tagging a rarer 
variant with higher risk nor did we observe evidence of other in- 
dependent association signals at any of the loci (P , 10
25
). 
Since no signal reached the threshold of genome-wide signifi- 
cance in our analysis (P , 2 × 1029), we applied the following 
marker selection scheme for identification of new UBC signals 
(Supplementary Material, Fig. S1). SNPs at previously reported 
loci and all SNPs with minor allele frequency (MAF) , 0.005 
were filtered out; of the remaining markers, we selected those 
with P-value of ,1 × 1025  and imputation information score 
.0.95 for further analysis. A total of 82 variants representing 
19   loci   fulfilled  these   criteria   (Supplementary   Material, 
Table S2). These 82 variants were tested for association with 
UBC, using in silico follow-up in a set of 1601 Dutch UBC 
cases and 1824 controls, genotyped with Illumina’s Human 
Hap CNV370 chip and imputed using 1000 Genomes low- 
coverage pilot haplotypes (released June 2010) and the 
HapMap3 haplotypes (release #2 February 2009) (13). Twelve 
of the 19 loci had imputed SNPs that could be used for follow-up 
and two of those, represented by rs62185668 on 20p12.2 and 
rs10784282 on 12q14.1, showed suggestive association with 
UBC risk in the same direction as the Icelandic dataset (Supple- 
mentary Material, Table S2A). For the other 10 loci, the associ- 
ation signal did not replicate in the Dutch GWAS. Nine markers, 
representing 7 loci, were not present in the Dutch GWAS dataset 
and no good proxies were identified. These markers, along with 
rs62185668 and rs10784282 that showed suggestive results in 
silico, were genotyped with single SNP assays in UBC case – 
control sample sets from The Netherlands (2098 cases and 
4545 controls—including the samples used in the GWAS) and 
Sweden (343 cases and 1264 controls) (Supplementary Material, 
Table S2B). Only rs62185668 on 20p12.2 showed suggestive as- 
sociation with UBC in both sample sets and this locus was 
selected for a further follow-up. 
In the Icelandic GWAS dataset, three markers at 20p12.2 
show the strongest association with UBC; two single nucleotide 
variants rs62185668 and rs4813953 and an INDEL rs148953085 
(4 bp deletion) (Fig. 1 and Table 2). Because none of the markers 
were present on the chips used for genotyping, all three variants 
were directly genotyped to verify the accuracy of the Icelandic 
imputation. Comparing the counts of the risk alleles of the 
three markers among 2633 individuals, the correlation between 
imputation and direct genotyping was .0.97 for all variants. 
The variants rs62185668, rs4813953 and rs148953085 were 
genotyped in a total of 5241 UBC cases and 10 456 controls 
from 11 European UBC case – control sample sets (Table 1). 
Using information on over 18 000 cases and controls from the 
12 study populations directly genotyped for all three markers, 
we determined that rs62185668 and rs148953085 are highly cor- 
related (r
2  
¼ 0.96) and can be assumed to represent the same 
association signal. For convenience, this signal will hereafter 
be referred to using rs62185668. The correlation between 
rs62185668 and rs4813953 is moderate (r
2  
¼ 0.50). The evi- 
dence for replication of the UBC associations in non-Icelandic 
populations was significant (OR ¼ 1.17, P ¼ 2.5 × 1027   for 
rs62185668 and OR ¼ 1.13, P ¼ 6.2 × 1026   for rs4813953) 
and showed no evidence of heterogeneity (Table 2). Combined 
with the Icelandic data, the overall association passed the thresh- 
old of genome-wide significance for both variants (rs62185668; 
OR ¼ 1.19, P ¼ 1.5 × 10211  and rs4813953; OR ¼ 1.16, P ¼ 
2.1 × 10210) (Table 2). 
We ran conditional analysis on rs62185668 and rs4813953 
where we adjusted the results for each variant, using the other 
variant as a covariate, including all individuals that had been 
genotyped by single-variant assays for both markers. Once 
adjusted for the other, the effect of each marker became consid- 
erably smaller and the P-value much less significant (P . 0.01), 
suggesting that both markers are capturing the same signal al- 
though neither marker appears to fully explain the association 
(Supplementary Material, Table S3). 
We tested whether the risk variants at 20p12.2 associate with 
disease subtypes that carry different risks of progression. Clinic- 
al and molecular evidence suggests that UBC can develop along 
at least two distinct pathways, one predicted to have low risk of 
progression (tumors confined to the bladder mucosa and not 
poorly differentiated) and the other having a high risk of progres- 
sion (tumor invasion in or beyond the lamina propria or poorly 
differentiated) (21). Using the same classification of cases, we 
found that the frequency of rs62185668 and rs4813953 was not 
different between patients with tumors of different risks of pro- 
gression (P ¼ 0.84 and 0.23, for rs62185668 and rs4813953, 
respectively) (Supplementary Material, Table S4). Neither 
rs62185668 nor rs4813953 associates with gender or age at diag- 
nosis of UBC. 
The UBC risk variants are located in a non-coding region on 
20p12.2. The closest gene is JAG1 (jagged1), located ∗300 kb 
upstream of rs62185668, rs148953085 and rs1327235 (Fig. 1). 
JAG1 is the ligand for the NOTCH family of transmembrane 
receptors that play important roles in determining cell fate and 
stem cell maintenance, promote cell survival and have been 
implicated in many forms of cancer (22). An immunohistochem- 
ical study on 70 bladder carcinomas and 10 samples of normal 
urothelium revealed significantly decreased NOTCH1 and 
JAG1 staining in tumor tissues (23). We assessed the expression
5549  5549  
 
 
 
 
 
 
 
Figure 1. Regional association plot for the 20p12.2 locus. The figure shows the 2log10 P-values (left vertical axis) of variant associations with UBC in the Icelandic 
discovery samples against their positions at the 20p12.2 locus. The purple circle highlights the most significant SNP, rs4813953, in the discovery analysis and circles 
corresponding to other SNPs are color coded to reflect their LD with rs4813953 estimated in the Icelandic dataset. The red line indicates recombination rates (right 
axis), based on the Icelandic recombination map for males and females (19) combined with the peaks indicating recombination hotspots defining LD blocks. Known 
genes in the region are shown underneath the plot, taken from the UCSC genes track in the UCSC genome browser. All positions are in NCBI Build 36 coordinates. The 
plot was created using a standalone version of the LocusZoom software (http://csg.sph.umich.edu/locuszoom/) (20). 
 
of JAG1 mRNA in bladder tissues (4 normal urothelial samples 
and 181 tumors) profiled on the Affymetrix U133Plus2 expres- 
sion microarray (24). Consistent with the previous study, there 
was a trend towards lower JAG1 expression in bladder tumors 
from the level in normal urothelium (t-test P-value ¼ 0.063; 
Supplementary Material, Table S5). Furthermore, in the large 
majority of our panel of 45 UBC cell lines, expression of JAG1 
mRNA is less than in than normal human urothelial cells (Sup- 
plementary Material, Fig. S2). 
We next attempted to determine if the UBC risk variants asso- 
ciate with differential expression of JAG1 in urothelial cells. 
Normal urothelium is hard to obtain because of the difficulty 
in isolating the few layers of urothelial cells from the stroma 
beneath it and no large-scale expression datasets are available 
for this tissue type. We therefore assessed JAG1 expression in 
34 low-passage normal human urothelial cell strains, using 
quantitative real-time RT-PCR and correlated expression with 
genotype of rs62185668, adjusting for number of passages. 
JAG1 showed a trend towards lower expression in carriers of 
rs62185668-A  (P-value ¼ 0.11,  effect ¼ 20.15  per  allele) 
(Supplementary Material, Fig. S3). We searched for eQTLs for 
JAG1 in the GTEx database  (http://www.broadinstitute.org/ 
gtex) which contains eQTLs for nine different tissue types, 
albeit no data from urothelium. Lung tissue was the only tissue 
type reporting eQTLs for JAG1; these eQTLs were not corre- 
lated to our UBC markers. We then genotyped rs62185668 in 
67 tumor samples for which DNA was available and correlated 
the  genotype  with  JAG1  expression,  JAG1  locus  loss  in 
tumors,  stage  and  grade  of  the  tumor,  mutation  status  of 
FGFR3 and TP53, and the presence or absence of the recently 
defined MRES epigenetic phenotype (24). While JAG1 expres- 
sion is associated with its copy number, rs62185668 genotype 
did not show significant association with any of the tumor pheno- 
types. However, taking into account bladder tumor heterogen- 
eity, the number of tumors is too small to conclusively rule out 
modest effects. 
Analysis was undertaken to explore the potential functional 
roles of the UBC risk variants. First, we identified a set of variants 
at the 20p12.2 locus that are strongly correlated with rs62185668 
or rs4813953 (r
2  
. 0.9). A total of 12 variants were correlated 
with rs62185668 with r
2  
. 0.9 but no variant was found that 
had this strong correlation with rs4813953 (the most highly 
correlated marker is rs62185671 with r
2  
¼ 0.86). We then cross- 
referenced the selected variant locations with potential biologic- 
al functional features according to The Encyclopedia of DNA 
Elements project (25 – 27). The most-highly annotated variant 
is the INDEL rs148953085 located within a predicted DNaseI 
hotspot with strong signal in 32 cell types (Supplementary Ma- 
terial, Table S6). According to a ChIP-Seq analysis, this site 
also  binds  the  C-FOS,  C-JUN  and  GATA2  transcription 
factors in the umbilical vein endothelial cell line HUVEC. Fur- 
thermore this site is in a region annotated as an enhancer based on
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Table 1.  Case – control groups used in the study  
Study group No. of cases No. of controls Average age at 
diagnosis (range) 
% males (cases) Study type 
Discovery group (GWA) 
Iceland 
 
1670 
 
90 180 
 
68 (20 – 95) 
 
76 
 
Population-based 
The Netherlandsa 1601 1824 62 (25 – 93) 81 Population-based 
The Netherlandsa 2340 4545 64 (23 – 93) 81 Population-based 
UK, Leeds 771 574 73 (30 – 101) 71 Hospital-based 
Italy, Torino 332 391 63 (40 – 75) 100 Hospital-based 
Italy, Brescia 183 193 63 (22 – 80) 100 Hospital-based 
Belgium, Leuven 201 385 68 (40 – 93) 86 Population-based 
Eastern Europe (Hungary, Romania, Slovakia) 214 533 65 (36 – 90) 83 Hospital-based 
Sweden, Stockholm 352 1350 69 (32 – 97) 67 Population-based 
Spain, Zaragoza 246 1844 65 (27 – 94) 87 Hospital-based 
Germany, Dortmund 213 298 65 (20 – 91) 86 Hospital-based 
Germany, Lutherstadt Wittenberg 197 239 71 (35 – 89) 75 Hospital-based 
Germany Neuss 217 104 71 (26 – 93) 78 Hospital-based 
Total 6936 99 682    
 
 
 
 
 
 
 
 
 
 
In silico replication (GWA) 
 
Follow-up groups 
 
 
 
 
 
 
 
 
 
 
 
 
aThe Dutch dataset used for in silico replication is a subset of the total Dutch case – control sample set used for follow-up 
 
 
 
Table 2.  Association of rs62185668[A] and rs4813953[T] on 20p12.2 with UBC 
 
Study population rs62185668[A] 
Frequency 
 
OR 
 
95% CI 
 
P-value 
 
Phet        I
2
 
rs4813953[T] 
Frequency                OR      95% CI        P-value         Phet        I
2
 
Cases     Controls  Cases     Controls     
Discovery groups (GWA) 
Icelanda 0.290     0.253 
 
1.26 
 
1.14, 1.40 
 
5.84E206 
  
0.425 
 
0.367 
 
1.26 
 
1.15, 1.38 
 
9.06E207 
Follow-up groups           
The Netherlands 0.260 0.236 1.13 1.04, 1.23 0.0037  0.396 0.368 1.13 1.05, 1.21 0.0019 
UK 0.266 0.231 1.20 1.00, 1.45 0.052  0.422 0.394 1.12 0.95, 1.32 0.17 
Italy, Torino 0.287 0.233 1.33 1.04, 1.69 0.023  0.451 0.399 1.23 0.99, 1.53 0.057 
Italy, Brescia 0.243 0.237 1.03 0.70, 1.52 0.86  0.406 0.369 1.17 0.86, 1.59 0.33 
Belgium 0.247 0.221 1.16 0.86, 1.55 0.34  0.415 0.367 1.22 0.95, 1.57 0.13 
Eastern Europe 0.260 0.253 1.03 0.76,1.41 0.84  0.390 0.403 0.95 0.73, 1.23 0.68 
Sweden 0.253 0.222 1.19 0.97, 1.46 0.10  0.389 0.377 1.05 0.88, 1.27 0.58 
Spain 0.278 0.250 1.15 0.93, 1.43 0.20  0.409 0.394 1.06 0.88, 1.29 0.52 
Germany Dortmund 0.300 0.233 1.41 1.02, 1.95 0.038  0.448 0.379 1.33 1.00, 1.76 0.046 
Germany, Luth/Witt 0.262 0.238 1.14 0.80, 1.61 0.47  0.391 0.362 1.13 0.85, 1.51 0.40 
Germany, Neuss 0.313 0.221 1.60 1.08, 2.37 0.019  0.433 0.375 1.27 0.90, 1.80 0.17 
Follow-up groupsb 0.270 0.234 1.17 1.10, 1.24 2.50E207 0.78     0.0 0.413 0.381 1.13 1.07, 1.19 6.20E206     0.86     0.0 
All combinedb 0.271 0.236 1.19 1.13, 1.26 1.50E211 0.70     0.0 0.414 0.380 1.16 1.11, 1.21 2.10E210     0.56     0.0 
 
All P-values shown are two sided. Shown are the allelic frequencies of variants in affected and control individuals and the allelic OR with P-values based on the 
multiplicative model. 
aResults adjusted by the method of genomic control (see Supplementary Material). Of the Icelandic subjects, 826 cases and 44 604 controls were directly genotyped, 
the remaining cases and controls are individuals that had not been chip typed, but for which genotype probabilities were imputed using methods of familial imputation 
(17). 
bFor the combined study populations, the control frequency was the average, unweighted control frequency of the individual populations, while the OR and the P-value 
were estimated using the Mantel – Haenszel model. 
 
histone mark data from four cell types (27), it has RegulomeDB 
score of 4 (28) and Gerp score of 2.62 (29). The second strong- 
est  candidate  is  the  SNP  variant  rs62185663 (r
2  
¼ 1  with 
rs62185668) which is located within a predicted DNaseI 
hotspot with strong signal in 17 cell types. This site is in a 
region annotated as an enhancer based on histone mark data 
from two cell types; it has RegulomeDB score of 4 (28). 
Heterozygous mutations in JAG1 cause Alagille syndrome 
(arteriohepatic dysplasia; OMIM 118450), a multisystem dis- 
order primarily affecting the liver, heart, skeleton, eye and 
face. Previously, common variants at the JAG1 locus have 
been reported that associate with bone mineral density (BMD) 
(rs3790160, rs2273061) (30,31) and various measures of blood 
pressure (BP) (rs1327235) (32). Neither rs62185668 nor 
rs4813953 is correlated with the BMD variants (r
2  
, 0.04), 
whereas rs62185668 shows modest correlation with the BP var- 
iants (r
2  
¼ 0.32) (Supplementary Material, Table S7). We tested 
the association of the BMD and BP variants with UBC and, con- 
versely, whether the UBC variants associated with BMD or BP, 
using the extensive genotype and phenotype data available at
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deCODE (Supplementary Material, Table S8). The BMD and 
BP variants showed no association with bladder cancer in the 
Icelandic data (Supplementary Material, Table S8), whereas 
the UBC variant rs62185668 showed association with several 
measures of bone density with P , 3 × 1024. To further test 
the association between the UBC variants and BMD, we used 
data from the meta-analysis of GWAS for BMD of the femoral 
neck  (FN-BMD; n ¼ 32 961)  and  lumbar  spine  (LS-BMD; 
n ¼ 31 800), including ∗2.5  million autosomal genotyped or 
imputed SNPs from 17 studies from populations across North 
America, Europe, East Asia and Australia (http://www.gefos. 
org/?q=content/data-release, downloaded February 12, 2014) 
(31). rs4813953 was directly tested in the meta-analysis but 
the marker rs62185668 was not present in the dataset so a 
perfect surrogate (D′ ¼ 1, r
2  
¼ 1, according to http://www. 
broadinstitute.org/mpg/snap based on 1000 Genomes pilot 1) 
was tested instead. In this large sample set, rs4813953 and 
rs6077985 showed association with FN-BMD with P-values of 
0.003  and  0.001,  respectively,  but  did  not  associate  with 
LS-BMD (P ¼ 0.41 and 0.03, respectively). Given that the 
meta-analysis has far more power and greater sample size than 
the Icelandic study alone, we conclude that the additional evi- 
dence from non-Icelandic studies does not replicate the associ- 
ation with the same effect observed initially in Iceland and that 
the UBC SNPs are unlikely to have an effect on BMD. 
Finally, a suggestive association between a variant at 20p12.2 
(rs6104690, MAF ¼ 0.44) and  UBC was recently  reported, 
however, this association (OR ¼ 0.89, P ¼ 7.13 × 1027)  did 
not reach the level of genome-wide significance (15). The var- 
iants reported here to associate with genome-wide significance 
with UBC have a lower frequency and a stronger effect than 
the reported variant rs6104690 and show low-to-moderate cor- 
relation with this variant (r
2  
between rs6104690 and each of 
the variants rs62185668 and rs4813953 is 0.30 and 0.14, respect- 
ively). We performed conditional analysis where we adjusted the 
association results for rs62185668 for rs6104690 and vice versa, 
using data on 826 UBC cases and 44 604 controls in the Icelandic 
population (Supplementary Material, Table S9). After adjust- 
ment  for  rs62185668,  no  signal  remained  at  rs6104690 
whereas the association signal of rs62185668 was not affected 
by adjustment with rs6104690. Finally, a variant at 6p22.3, 
rs4510656, was also reported to have a suggestive association 
with UBC (OR ¼ 0.89, P ¼ 6.7 × 1027) (15). We assessed the 
association between rs4510656 and UBC in the Icelandic and 
Dutch GWAS data. In both datasets, the variant showed a 
weak effect in the same direction as reported (combined OR ¼ 
0.94, P ¼ 0.061); however, the results from combined analysis 
of the Icelandic, Dutch and published GWAS failed to reach 
the threshold for genome-wide significance (OR ¼ 0.91, 95% 
CI (0.88, 0.94), P ¼ 3.6 × 1027, Phet  ¼ 0.29, I
2 ¼ 18.9). 
 
 
DISCUSSION 
 
In this study, we discovered and validated associations between 
UBC and common markers at 20p12.2. The strongest association 
signal is represented by two moderately correlated markers 
rs62185668 and rs4813953. Conditional analysis showed that 
neither variant retains a significant association after adjustment 
for the other, indicating that they may represent the same signal. 
Using the sequence information of 2230 Icelanders who have 
been  whole-genome  sequenced  to  an  average  sequencing 
depth of 22×, we can impute variants down to ∗0.1% frequency 
into our case – control population. We scrutinized the region 
flanking rs62185668 (1 Mb on either side) and did not observe 
any variants that could better explain the association signal 
than rs62185668 and rs4813953. However, it should be noted 
that even at this coverage, current WGS technology has pro- 
blems resolving some regions of the genome, such as repetitive 
sequences and first exons of protein coding genes. We can there- 
fore not exclude that the causative variant still remains to be 
found. 
The closest gene to the UBC variants at 20p12.2 is the 
NOTCH1 ligand, JAG1, prompting speculations that this gene 
may contribute to susceptibility to UBC. The Notch pathway 
has been shown to play a complex role in cancer where its role 
is highly dependent on cell type and context, being implicated 
both as a tumor promoter and suppressor (22). Activation of 
Notch  pathways is  commonly  observed  in  different  cancer 
types and inhibitors of Notch signaling are being tested as 
cancer  medicines  (33).  Reports  of  expression  of  Notch 
pathway genes in UBC have been conflicting. In the Expression 
Atlas (a study that compiles 5372 samples from 206 different 
studies generated on the HG-U133A array platform) both 
NOTCH1 and JAG1 are reported to be upregulated in UBC 
(34)  and  a  recent  study  on  131  bladder  tumors,  released 
through The Cancer Genome Atlas research network, reported 
upregulation of JAG1 expression in 12 tumors (35). However, 
a study that assessed the presence of the NOTCH1 and JAG1 pro- 
teins by immunohistochemistry of bladder tumors and normal 
urothelium and our own results suggest that JAG1 is downregu- 
lated in bladder tumors and UBC cell lines. Notably, post- 
operative disease-free survival time in patients with papillary 
tumors with low Notch1 and Jag1 expression has been found 
to be significantly shorter than that in patients with other expres- 
sion patterns (23). Finally, NOTCH1 is on the long arm of 9q 
which is deleted in a high fraction of both superficial and 
muscle-invasive UBC (36). 
In conclusion, we have discovered an association between se- 
quence variants close to JAG1 at 20p12.2 and the risk of UBC. 
This finding brings the growing number of UBC risk loci identi- 
fied through GWAS to 13. 
 
 
MATERIALS AND METHODS 
Study subjects from Iceland 
Records of all UBC diagnoses were obtained from the ICR (http 
://www.krabbameinsskra.is). The ICR contains all cancer diag- 
noses in Iceland from January 1, 1955. The ICR contained 
records of 1983 Icelandic UBC patients diagnosed until Decem- 
ber 31, 2011. Recruitment of UBC cases was initiated in 2001 
and included all prevalent cases as well as newly diagnosed 
cases from that time. The participation rate for newly diagnosed 
cases since 2001 is 75%. Patients were recruited by trained 
nurses on behalf of the patients’ treating physicians, through 
special recruitment clinics. Participants in the study donated a 
blood sample and answered a lifestyle questionnaire. A total of 
826 patients (77% males; diagnosed from December 1964 to De- 
cember 2011) were included in a genome-wide SNP genotyping
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effort, using the Infinium II assay method and either the Sentrix 
HumanHap 300, HumanCNV370-duo or Omni Express Bead- 
Chips (Illumina). The median age at diagnosis for all consenting 
cases was 67.4 years (range 10 – 96 years) as compared with 68.9 
years for all UBC patients in the ICR. In addition to the chip- 
genotyped cases, we used information on 844 UBC cases 
without chip information whose genotype probabilities were 
imputed using methods of familial imputation (17). The 90 
180 controls used in this study consisted of individuals from 
other  ongoing  GWAS  at  deCODE.  No  individual  disease 
group is represented by .10% of the total control group. 
Cancer patients (prostate, breast, colorectal and lung) were ana- 
lyzed separately, and the frequency of the sequence variants 
studied did not differ from other controls. Samples from prostate, 
breast, colorectal and lung cancer patients as well as individuals 
used for the analysis of smoking variables come from other 
ongoing project at deCODE Genetics. The study was approved 
by the Data Protection Authority of Iceland and the National Bio- 
ethics Committee. Written informed consent was obtained from 
all patients, relatives and controls. Personal identifiers asso- 
ciated with medical information and blood samples were 
encrypted with a third-party encryption system for which the 
Data Protection Authority maintains the code. 
 
 
Study subjects from the Netherlands 
 
The Dutch patients were recruited for the Nijmegen Bladder 
Cancer Study (NBCS: http://dceg.cancer.gov/icbc/mem 
bership.html). The NBCS identified patients in the Eastern part 
of the Netherlands through the Netherlands Cancer Registry 
held by the Comprehensive Cancer Centre the Netherlands 
(IKNL). Patients diagnosed between 1995 and 2006 under the 
age of 75 years were selected and their vital status and current 
addresses updated through the hospital information systems of 
seven community hospitals and one university hospital 
(Radboud university medical center, Radboudumc). All patients 
still alive on August 1, 2007 were invited to the study by the 
Comprehensive Cancer Center on behalf of the patients’ treating 
physicians. A second group of patients, diagnosed between 2006 
and 2008, was invited in 2009, a third group, diagnosed between 
2008 and 2009, was invited in 2010 and a fourth group, diag- 
nosed between 2009 and 2011, was invited in 2012. In case of 
consent, patients were sent a lifestyle questionnaire to fill out 
and blood samples were collected by Thrombosis Service 
centers,  which  hold  offices  in  all  the  communities  in  the 
region. In total, 2654 patients were invited to participate. Of 
all the invitees, 1744 gave informed consent (66%): 1603 filled 
out the questionnaire (60%) and 1626 (61%) provided a blood 
sample. All the patients that were selected for the analyses 
were of self-reported European descent. The median age at diag- 
nosis was 64 (range 25 – 81) years. Eighty percent of the partici- 
pants were males. Data on tumor stage and grade were obtained 
through the cancer registry. 
The series of patients that was recruited through the Compre- 
hensive Cancer Centre was combined with a non-overlapping 
series of 465 bladder cancer patients who were (i) recruited pre- 
viously for a study on gene – environment interactions in three 
hospitals (Radboudumc, Canisius Wilhelmina Hospital, Nij- 
megen and Streekziekenhuis Midden-Twente, Hengelo, the 
Netherlands) (ii) consecutive bladder cancer patients from the 
Department of Urology, Radboudumc, Nijmegen, The Nether- 
lands. The median age at diagnosis was 64 (range 30 – 93) 
years. Eighty-five percent of these participants were males. 
Data on tumor stage and grade were obtained through the 
cancer registry. 
Additionally, another non-overlapping series of 249 consecu- 
tive bladder cancer patients from the Department of Urology, 
Erasmus Medical Center in Rotterdam, The Netherlands were 
included (81% males). All patients signed an informed consent 
form for their blood samples. 
The control group (46% males) was recruited within a project 
entitled ‘Nijmegen Biomedical Study’. Control individuals 
from the NBS were invited to participate in a study on gene – 
environment interactions in multifactorial diseases such as 
cancer.  The  details  of  this  study  were  reported  previously 
(37). Briefly, this is a population-based survey conducted by 
the Department for Health Evidence and the Department of 
Clinical Chemistry of the Radboudumc. Age- and sex-stratified 
randomly selected adult inhabitants of Nijmegen (n ¼ 22 451), a 
city located in the eastern part of the Netherlands, received an 
invitation to fill out a postal questionnaire including questions 
about lifestyle, health status and medical history, and to donate 
a blood sample for DNA isolation and biochemical studies. 
A total of 9350 (43%) persons filled out the questionnaire, of 
which 6468 (69%) responders donated blood samples. 
The study protocols of the Nijmegen Bladder Cancer Study 
and the Nijmegen Biomedical Study were approved by the Insti- 
tutional Review Board of the Radboud university medical center 
and all study subjects gave written informed consent. 
 
 
Study subjects from the United Kingdom 
Details of the Leeds Bladder Cancer Study have been reported 
previously (38). In brief, patients from the urology department 
of St James’s University Hospital, Leeds were recruited from 
August 2002 to March 2006. All those patients attending for 
cystoscopy or transurethral resection of a bladder tumor who 
had previously been found, or were subsequently shown, to 
have urothelial cell carcinoma of the bladder were included. Ex- 
clusion criteria were significant mental impairment or a blood 
transfusion in the past month. All non-Caucasians were excluded 
from the study leaving 764 patients. The median age at diagnosis 
of  the patients  was 73 years  (range  30 – 101). Seventy-one 
percent of the patients were male and 36% of all the patients 
had tumors with low risk of progression (pTaG1/2). The controls 
were recruited from the otolaryngology outpatients and ophthal- 
mology inpatient and outpatient departments at St James’s Hos- 
pital, Leeds, from August 2002 to March 2006. All controls of 
appropriate age for frequency matching with the cases were 
approached and recruited if they gave their informed consent. 
As for the cases, exclusion criteria for the controls were signifi- 
cant mental impairment or a blood transfusion in the past month. 
Also, controls were excluded if they had symptoms suggestive of 
bladder cancer, such as hematuria. 2.8% of the controls were 
non-Caucasian leaving 530 Caucasian controls for the study. 
Seventy-one percent of the controls were male. Data were col- 
lected  by  a  health  questionnaire  on  smoking  habits  and 
smoking history (non-, ex- or current smoker, smoking dose in 
pack-years), occupational exposure history (to plastics, rubber, 
laboratories, printing, dyes and paints, diesel fumes), family
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history of bladder cancer, ethnicity and place of birth and places 
of birth of parents. The participation response rate of cases was 
∗99%, that among the controls ∗80%. Ethical approval for the 
study was obtained from Leeds (East) Local Research Ethics 
Committee, project number 02/192. 
 
 
Study subjects from Torino, Italy 
 
The source of cases for the Torino bladder cancer study are two 
urology departments of the main hospital in Torino, the San Gio- 
vanni Battista Hospital (39). Cases are all Caucasian men, aged 
40 – 75 years (median 63 years) and living in the Torino metro- 
politan area. They were newly diagnosed between 1994 and 
2006  with  a  histologically  confirmed, invasive  or  in  situ, 
bladder cancer. Of all the patients with information on stage 
and grade, 56% were at low risk of progression (pTaG1/2). 
The sources of controls are urology, medical and surgical depart- 
ments of the same hospital in Torino. All controls are Caucasian 
men resident in the Torino metropolitan area. They were diag- 
nosed and treated between 1994 and 2006 for benign diseases 
(such as prostatic hyperplasia, cystitis, hernias, heart failure, 
asthma and benign ear diseases). Controls with cancer, liver or 
renal diseases and smoking-related conditions were excluded. 
The median age of the controls was 57 years (range 40 – 74). 
Data were collected by a professional interviewer who used a 
structured questionnaire to interview both cases and controls 
face to face. Data collected included demographics (age, sex, 
ethnicity, region and education) and smoking. For cases, add- 
itional data were collected on tumor histology, tumor site, size, 
stage, grade and treatment of the primary tumor. The participa- 
tion response rates were 90% for cases and 75% for controls 
resulting in 328 cases and 389 controls. Ethical approval for 
the study was obtained from Comitato Etico Interaziendale, 
A.O.U. San Giovanni Batista – A.). C.T.O./Maria Adelaide. 
 
 
Study subjects from Brescia, Italy 
The Brescia bladder cancer study is a hospital-based case – 
control study. The study was reported in detail previously (40). 
In short, the catchment area of the cases and controls was the 
Province of Brescia, a highly industrialized area in Northern 
Italy (mainly metal and mechanical industry, construction, trans- 
port and textiles) but also with relevant agricultural areas. Cases 
and controls were enrolled in 1997 – 2000 from the two main city 
hospitals. The total number of eligible subjects was 216 cases 
and 220 controls. The participation rate (enrolled/eligible) was 
93% (N ¼ 201) for cases and 97% (N ¼ 214) for controls. 
Only males were included. All cases and controls had Italian na- 
tionality and were of Caucasian ethnicity. All cases had to be 
residents of the Province of Brescia, aged between 20 and 80, 
and newly diagnosed with histologically confirmed bladder 
cancer. The median age of the patients was 63 years (range 
22 – 80). Twenty-nine percent of all the patients with known 
stage and grade had tumors with low risk of progression 
(pTaG1/2). Controls were patients admitted for various uro- 
logical non-neoplastic diseases and were frequency matched to 
cases on age, hospital and period of admission. The study was 
formally approved by the ethical committee of the hospital 
where the majority of subjects were recruited. A written 
informed  consent  was  obtained  from  all  participants.  Data 
were  collected  from  clinical  charts  (tumor  histology,  site, 
grade, stage, treatments, etc.) and by means of face-to-face inter- 
views during hospital admission, using a standardized semi- 
structured questionnaire. The questionnaire included data on 
demographics (age, ethnicity, region, education, residence, 
etc.), and smoking. ISCO and ISIC codes and expert assessments 
were used for occupational coding. Blood samples were col- 
lected from cases and controls for genotyping and DNA 
adducts analyses. 
 
 
Study subjects from Belgium 
 
The Belgian study has been reported in detail (41). In brief, cases 
were selected from the Limburg Cancer Registry and were 
approached through urologists and general practitioners. All 
cases were diagnosed with histologically confirmed urothelial 
cell carcinoma of the bladder between 1999 and 2004 and 
were Caucasian inhabitants of the Belgian province of 
Limburg. The median age of the patients was 68 years; 86% of 
all the patients were males. For the recruitment of controls, a 
request was made to the ‘Kruispuntbank’ of the social security 
for simple random sampling, stratified by municipality and 
socio-economic status, among all citizens .50 years of age of 
the province. The median age of the controls was 64 years; 
59% of the controls were males. Three trained interviewers 
visited cases and controls at home. Information was collected 
through a structured interview and a standardized food fre- 
quency questionnaire. In addition, biological samples were 
collected. Data  collected included medical  history, lifetime 
smoking history, family history of bladder cancer and a lifetime 
occupational  history.  Informed  consent  was  obtained  from 
all  participants  and the study  was approved by the ethical 
review board of the Medical School of the Catholic University 
of Leuven, Belgium. 
 
 
Study subjects from Eastern Europe 
 
The details of this study have been described previously (42). 
Cases and controls were recruited as part of a study designed 
to evaluate the risk of various cancers due to environmental 
arsenic exposure in Hungary, Romania and Slovakia between 
2002 and 2004. The recruitment was carried out in the counties 
of Bacs, Bekes, Csongrad and Jasz-Nagykun-Szolnok in 
Hungary; Bihor and Arad in Romania; and Banska Bystrica 
and Nitra in Slovakia. The cases (N ¼ 214) and controls (N ¼ 
533) selected were of Hungarian, Romanian and Slovak nation- 
alities. Bladder cancer patients were invited on the basis of histo- 
pathological examinations by pathologists. Hospital-based 
controls were included in the study, subject to fulfillment of a 
set of criteria. All general hospitals in the study areas were 
involved in the process of control recruitment. The controls 
were frequency matched with cases for age, gender, country of 
residence and ethnicity. Controls included general surgery, 
orthopedic and trauma patients aged 30 – 79 years. Patients 
with malignant tumors, diabetes and cardiovascular diseases 
were excluded as controls. The median age of the bladder 
cancer patients was 65 years (range 36 – 90); 83% of the patients 
were males. The median age of the controls was 61 years (range 
28 – 83); 51% of the controls were males. The participation rates 
among cases and controls were ∗70%. Of all the patients with
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known stage and grade information, 28% had a low-risk tumor 
(pTaG1/2). Clinicians took venous blood and other biological 
samples from cases and controls after consent forms had been 
signed. Cases and controls recruited to the study were inter- 
viewed by trained personnel and completed a general lifestyle 
questionnaire. Ethnic background for cases and controls was 
recorded along with other characteristics of the study population. 
Local ethical boards approved the study plan and design. 
 
 
Study subjects from Sweden 
The Swedish patients come from a population-based study of 
UBC patients diagnosed in the Stockholm region in 1995 – 
1996 (43). Blood samples from 352 patients were available out 
of a collection of 538 patients with primary urothelial carcinoma 
of the bladder. The average age at onset for these patients is 69 
years (range 32 – 97 years), and 67% of the patients are males. 
Clinical data, including age at onset, grade and stage of tumor, 
were prospectively obtained from hospitals and urology units 
in the region. The control samples came from blood donors in 
the Stockholm region and were from cancer-free individuals of 
both genders. The regional ethical committee approved the 
study and all participants gave informed consent. 
 
 
Study subjects from Spain 
 
The Spanish study patients were recruited from the Urology and 
Oncology Departments of Zaragoza Hospital between Septem- 
ber 2007 and June 2009. Two hundred and forty-six patients 
with histologically proven urothelial cell carcinoma of the 
bladder were enrolled (response 77%). Clinical information in- 
cluding age at onset, grade and stage was obtained from 
medical records. The median age at diagnosis for the patients 
was 65 years (range 27 – 94) and 87% were males. The 1844 
Spanish control individuals were part of a larger collection of 
control samples obtained from individuals who had attended 
the University Hospital in Zaragoza, Spain, for diseases other 
than cancer between November 2001 and May 2007. The con- 
trols were of both genders and median age was 52 years (range 
11 – 87). Controls were questioned to rule out prior cancers 
before drawing the blood sample. All patients and controls 
were of self-reported European descent. Study protocols were 
approved by the Institutional Review Board of Zaragoza Univer- 
sity Hospital. All subjects gave written informed consent. 
 
 
Study subjects from Germany 
 
The study subjects from Germany came from three different 
studies. 
 
(i)  The Neuss bladder cancer study. Details of the bladder 
cancer cases of this study have been published previously 
(44). The ongoing case – control series consists of 217 
bladder cancer cases and 105 controls from the Department 
of Urology, Lukasklinik Neuss, Germany, located ∗20 km 
from the Ruhr area. The median age at diagnosis was 72.9 
(range 26.1 – 93.4) years. Seventy-eight percent of the par- 
ticipants were males. Data on tumor stage and grade were 
obtained through the cancer registry. Forty-five percent 
of the patients had a low-risk tumor (pTaG1/2). The 105 
control individuals (64% males) (median age 42.4, range 
18.0 – 89.0) were cancer free. Data were collected from 
June 2009 to July 2010. The local ethics committee 
approved the study plan and design. 
(ii)  The Dortmund bladder cancer study. Details of the bladder 
cancer cases of this study have been published previously 
(43).  The case – control series consists  of  197 patients 
with a confirmed bladder cancer from the Department of 
Urology, St.-Josefs-Hospital Dortmund-Ho¨ rde, located in 
the Ruhr area, an area of former coal, iron and steel indus- 
tries and 240 controls from the same Department of 
Urology, admitted for treatment of benign urological dis- 
eases, enrolled from July 2009 to July 2010. The median 
age  at  diagnosis  was  71.2  (range  35.0 – 89.2)  years. 
Seventy-five percent of the participants were males. Sixty 
percent of the patients had tumors with low risk of progres- 
sion (pTaG1/2). The 240 control individuals (77% males) 
were cancer free and frequency matched for age with the 
cases  (median  age  70.7,  range  21.7 – 100).  The  local 
ethics committee approved the study plan and design. 
(iii)  The Lutherstadt Wittenberg study. Details of the bladder 
cancer cases of this study have been reported previously 
(44 – 46). In brief, 221 patients with a confirmed bladder 
cancer from the Department of Urology, Paul Gerhardt 
Foundation, Lutherstadt Wittenberg, Germany, were 
included. Patients were enrolled from December 1995 to 
January 1999. Exclusion criterion was a missing written 
informed consent into the study. The median age of the 
patients was 65 years (range 20 – 91); 86% of the patients 
were males. A total of 214 controls were from the same de- 
partment of urology, but were admitted for treatment of 
benign urological diseases. Exclusion criteria were malig- 
nant disease in the medical history or a missing written 
informed consent. The median age of the controls was 68 
years (range 29 – 91); 84% of the controls were males. 
Data were collected from July 2000 to May 2005. All 
cases and controls were Caucasians, which was confirmed 
by questionnaire-based documentation of nationality. 
Cases and controls were matched for age. Data collected 
in cases and controls include age, gender, a complete docu- 
mentation of occupational activities performed at least for 6 
months, documentation of work places with known bladder 
cancer risk over the entire working life, exposures to known 
or suspected occupational bladder carcinogens, lifetime 
smoking habits, family history of bladder cancer, numbers 
of urinary infections treated by drugs during the previous 
10 years, place of birth and places of residency for .10 
years. For bladder cancer cases, data on tumor staging, 
grading and treatment were taken from the records. First 
diagnosis of bladder cancer was recorded from July 1979 
to January 1999. The local ethics committee approved the 
study plan and design. 
 
 
Genome-wide genotyping and imputations of untyped 
variants 
 
The Icelandic chip-typed samples were assayed with the Illumina 
HumanHap300, HumanCNV370, HumanHap610, Human- 
Hap1M, HumanHap660, Omni-1, Omni 2.5 or Omni Express 
bead chips. SNPs were excluded if they had (i) yield ,95%,
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(ii) minor allele frequency ,1% in the population, (iii) signifi- 
cant   deviation   from   Hardy – Weinberg   equilibrium   (P , 
0.001), (iv) if they produced an excessive inheritance error rate 
(over 0.001) or (v) if there was substantial difference in allele fre- 
quency between chip types (from just a single chip if that 
resolved all  differences,  but  from all  chips  otherwise).  All 
samples with a call rate ,97% were excluded from the analysis. 
For the HumanHap series of chips, 308 840 SNPs were used for 
long-range phasing, whereas for the Omni series of chips 642 
079 SNPs were included. The final set of SNPs used for long- 
range phasing was composed of 785 863 SNPs. 
Variants were imputed based on WGS data from 2230 Icelan- 
ders, sequenced at a minimum depth of 10× (average 22×). Ap- 
proximately 34.2 million SNPs and small indel variants were 
imputed based on this set of individuals. A detailed description 
of imputation methods used for the Icelandic population has 
been published recently (18). In brief, sequencing by synthesis 
was performed on Illumina GAIIx and HiSeq2000 instruments. 
Association testing 
Case – control association testing 
Logistic regression was used to test for association between se- 
quence variants and disease, treating disease status as the re- 
sponse and expected allele counts from imputation or allele 
counts from direct genotyping as covariates. The analysis 
included assessment of chromosome X. Testing was performed 
using the likelihood ratio statistic. When testing for association 
using the in silico genotypes, controls were matched to cases 
based on the informativeness of the imputed genotypes, such 
that for each case C controls of matching informativeness 
where chosen. Failing to match cases and controls will lead to 
a highly inflated genomic control factor, and in some cases 
may lead to spurious false positive findings. The informativeness 
of each of the imputation of each of an individual’s haplotypes 
was estimated by taking the average of 
⎧ 
e − u
SNPs that were identified through sequencing were imputed into 
all Icelanders who had been phased with long-range phasing 
⎪⎨ 
a(e,  u) =  1 − u 
,   e ≥ u
using the same model used by IMPUTE. 
The full GWAS results provide specific information on the 
u − e 
,   e , u 
u
genetic characteristics of the whole Icelandic nation, precluding 
full disclosure of the data. Association results for all variants 
with P-value , 10
24
, MAF . 0.005 and imputation informa- 
tion  score  .0.95  are  shown  in  Supplementary  Material, 
Table S10. 
The Dutch GWAS has been described previously (13). In 
brief, 1631 Dutch cases and 1824 Dutch controls were assayed 
with the Illumina HumanHap300 or HumanHapCNV370 (Illu- 
mina, SanDiego, CA, USA). SNPs were excluded if they had 
MAF ,0.01, were not in Hardy – Weinberg equilibrium (P , 
10 – 5) or had different frequency for the two chip types used 
(P , 10 – 5). For imputation into the Dutch dataset, we 
used 
292 650 autosomal SNPs present on both chip types and that 
passed  QC to  impute  an  additional  7 543 837  ungenotyped 
SNPs using the IMPUTE v2.1 software (47,48) and a training 
set consisting of the combined 1000 Genomes low-coverage 
pilot haplotypes (released June 2010, 120 chromosomes) and 
the HapMap3 haplotypes (release #2 February 2009, 1920 chro- 
mosomes) downloaded from http://mathgen.stats.ox.ac.uk/imp 
ute/impute_v2.html#filtered_1kg_hm3_haps. 
 
 
 
Single track  variant genotyping 
 
Genotyping of single SNP was carried out by deCODE Genetics 
in Reykjavik, Iceland, applying the Centaurus (Nanogen) plat- 
form (49). The quality of the imputation was evaluated by com- 
paring imputed genotypes to genotypes obtained by using the 
assay. The concordance was .97%. Positive and negative con- 
trols were present on all genotyping plates in order to ensure 
correct genotyping. Genotyping of the indel variant 
rs148953085 was done by PCR amplification followed by size 
fractionation on Applied Biosystems model 3730 sequencer, 
using Genescan (v. 3.0) peak-calling software. Alleles were 
 
over all SNPs imputed for the individual, where e is the expected 
allele count for the haplotype at the SNP and u is the population 
frequency  of  the  SNP.  Note  that  a(u,u) ¼ 0  and  a(0,u) ¼ 
a(1,u) ¼ 1. The mean informativeness values cluster into groups 
corresponding to the most common pedigree configurations used 
in the imputation, such as imputing from parent into child or from 
child into parent. Based on this clustering of imputation inform- 
ativeness, we divided the haplotypes of individuals into seven 
groups of varying informativeness, which created 27 groups of 
individuals of similar imputation informativeness; 7 groups of 
individuals with both haplotypes having similar informativeness, 
21 groups of individuals with the two haplotypes having different 
informativeness, minus the one group of individuals with neither 
haplotype being imputed well. Within each group, we calculate 
the ratio of the number of controls and the number of cases, and 
choose the largest integer C that was less than this ratio in all 
the groups. For example, if in one group there are 10.3 times as 
many controls as cases and if in all other groups this ratio was 
greater, then we would set C ¼ 10 and within each group random- 
ly select 10 times as many controls as there are cases. 
 
Quantitative trait association testing 
A generalized form of linear regression was used to test for associ- 
ation between sequence variants and BMD or BP. Let y be the 
vector of quantitative measurements, and let g be the vector of 
expected allele counts for the SNP being tested. We assume the 
quantitative measurements follow a normal distribution with a 
mean that depends linearly on the expected allele at the SNP and 
a variance covariance matrix proportional to the kinship matrix: 
 
y ∗N (a + bg, 2s2 F), 
 
where
called  using  an  internal  allele-calling  program  (50).  The                                               ⎧ 
1
sequences of the primers used for genotyping were as follows: 
forward    5′-(GTGGGTAAGGCAAACCAAAA)-3′,   reverse 
5′-(AGGTTCAGTCTGCCCTGAAA)-3′. 
Fij  = 
⎨     
,    i     j 
2                , ⎩ 
2kij ,   i = j
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is the kinship matrix as estimated from the Icelandic genealogical 
database. It is not computationally feasible to use this full model 
and we therefore split the individuals with in silico genotypes 
and BMD and BP measurements into smaller clusters. Here, we 
chose to restrict the cluster size to at most 300 individuals. 
The maximum likelihood estimates for the parameters a, b 
and s
2 
involve inverting the kinship matrix. If there are n indivi- 
duals in the cluster, then this inversion requires O(n
3
) calcula- 
tions, but since these calculations only need to be performed 
once, the computational cost of doing a genome-wide associ- 
ation scan will only be O(n
2
) calculations; the cost of calculating 
the maximum likelihood estimates if the kinship matrix has 
already been inverted. 
 
 
Association analysis of follow-up datasets 
 
For association analysis of the follow-up datasets, we used a 
standard likelihood ratio statistic, implemented in the NEMO 
software (51) to calculate two-sided P-values for each individual 
allele, assuming a multiplicative model for UBC risk, i.e. the 
bladder cancer risk multiplies by the number of risk alleles a 
person  carries.  Results  from  multiple  case – control  groups 
were combined using a Mantel – Haenszel model in which the 
groups were allowed to have different population frequencies 
for alleles and genotypes but were assumed to have common 
ORs (52). 
Stratified analyses were conducted by smoking and by UBC 
aggressiveness. For the latter, all patients for whom detailed hist- 
ology information was available were classified with regards to 
risk of progression, based on stage and  grade information. 
Patients with ‘low risk of progression’ were defined as having 
TNM stage pTa in combination with WHO 1973 differentiation 
Grade 1 or 2 or WHO/ISUP 2004 low grade. All other tumors 
were classified as ‘high risk of progression’ (stage pTis or ≥ 
pT1 or WHO 1973 Grade 3 or WHO/ISUP 2004 high grade). 
 
 
Conditional analysis 
For the two variants rs62185668 and rs4813953, their associ- 
ation was tested conditional on the observed association of the 
others. For the replication cohorts for which direct genotypes 
were available, the conditional analysis was done using the 
Nemo software (51). For the Icelandic cohort, the conditional 
analysis was done using the same method used for the genome- 
wide association analysis that takes into account the imputation 
uncertainty. However, the analysis was restricted to the 863 
cases and 46 602 controls that have been chip typed as the imput- 
ation is much less reliable for individuals with genotype prob- 
abilities estimated based on information from chip-typed 
relatives. While this does not affected the single marker associ- 
ation analysis, very uncertain estimates for genotype probabil- 
ities for the variant that is conditioned on make the conditional 
analysis harder to interpret. 
 
 
Heterogeneity calculations 
 
Heterogeneity was tested by comparing the null hypothesis of 
the effect being the same in all populations to the alternative hy- 
pothesis of each population having a different effect using a like- 
lihood ratio test. I
2 
lies between 0 and 100% and describes the 
proportion of total variation in study estimates that is due to het- 
erogeneity (53). 
 
 
Bioinformatics methods 
A search was carried out to detect overlaps between variant loca- 
tions and known bioinformatic features. We retrieved data from 
UCSC test browser (HG19 build 37) (26). We accessed feature 
tracks relevant to the bladder tissue containing genome position- 
al information and identified those features that overlapped 
with the SNP. We also accessed HaploReg v2 (27) and Regulo- 
meDB (28). We accessed The Gene Expression Atlas by EBI for 
reports on expression of JAG1 in bladder cancer (54). These are 
recognized draft quality data and were used as is without quality 
filtering. 
 
 
Assessment of expression in cell lines and tissues 
 
Expression of JAG1 in tumor and normal UBC tissues was 
measured by Affymetrix HG-U133 Plus 2.0 arrays as described 
(55). The microarray data are available from ArrayExpress 
(www.ebi.ac.uk/arrayexpress/)  under  the  accession  numbers 
E-MTAB-1803 for the muscle-invasive bladder tumors and 
E-MTAB-1940   for   the   non-muscle-invasive   tumors   and 
normal samples. 
Bladder cell lines used in this study and gene expression pro- 
filing using GeneChip Human Genome U133 Plus 2.0 Arrays 
(Affymetrix) were as described (56). Normal human urothelial 
cells (NHUC) were isolated from human ureters obtained at 
nephrectomy (57) and were used either uncultured (passage 0) 
or cultured to low passage (passages 1 or 2). Total RNA was 
extracted directly from passage 0 NHUC or from cells cultured 
to 70 – 80% confluence using an RNeasy Mini Kit (Qiagen). 
cDNA was synthesized using 1 mg of total RNA and Superscript 
II (Invitrogen) according to the manufacturer’s instructions. 
Expression of JAG1 in low-passage NHUC was assessed by 
quantitative real-time RT-PCR using a TaqMan assay 
(Hs01070032_m1; Applied Biosystems). Levels of expression 
were normalized to SDHA (Hs00417200_m1) and measured 
relative to cell line 97-18. 
 
 
SUPPLEMENTARY MATERIAL 
Supplementary Material is available at HMG online. 
 
 
ACKNOWLEDGEMENTS 
 
We thank the individuals that participated in the study and whose 
contribution made this work possible. We also thank the person- 
nel at all the recruitment centres. We acknowledge the cancer 
registries in Iceland and the Netherlands for assistance in the as- 
certainment of the Icelandic and Dutch UBC patients. 
 
Conflict of Interest statement. None declared. 
 
 
FUNDING 
 
This work was supported by the following funding agencies. 
Collection of samples and data in Iceland and the Netherlands
5557  5557  
 
 
 
was funded in part by the European Commission (POLYGENE: 
LSHC-CT-2005) (grant number 018827) and a research invest- 
ment grant of the Radboud university medical centre (Radbou- 
dumc).  The  Leeds  Bladder  Cancer  Study  was  funded  by 
Cancer Research UK and Yorkshire Cancer Research. Torino 
Bladder Cancer Case Control Study was supported by a grant 
to ECNIS (Environmental Cancer Risk, Nutrition and Individual 
Susceptibility), a network of excellence operating within the 
European Union 6th Framework Program, Priority 5: ‘Food 
Quality and Safety’ (Contract No. 513943); by a grant of the 
Compagnia di San Paolo—Human Genetics Foundation 
(HuGeF), the Italian Association for Cancer Research, Italy 
and the Piedmont Region Progetti di Ricerca Sanitaria Finaliz- 
zata. The Belgian bladder cancer study was funded by the 
Flemish government and by the health authorities of the 
Belgian province of Limburg. The Swedish study was funded 
by the  Swedish Cancer  Society  and  the Swedish Research 
Council. J.I.M. is funded by Red Tema´tica de Investigacio´n 
Cooperativa en Ca´ncer (grant number RD06/0020/1054). The 
expression array work was supported by INSERM, CNRS, Insti- 
tut Curie and by grants from INCa (INCA_1053 and 
INCA_5176),  La  Ligue  Nationale  Contre  le  Cancer  (FR: 
e´quipe labellise´e), and the program ‘Carte d’Identite´ des 
Tumeurs’, initiated, developed and funded by Ligue Nationale 
Contre le Cancer. 
 
 
 
REFERENCES 
 
1.  Ploeg, M., Aben, K.K.H. and Kiemeney, L.A. (2009) The present and future 
burden of urinary bladder cancer in the world. World J. Urol., 27, 289 – 293. 
2.  Ferlay, J., Shin, H.-R., Bray, F., Forman, D., Mathers, C. and Parkin, D.M. 
(2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 
2008. Int. J. Cancer J. Int. Cancer, 127, 2893 – 2917. 
3.  Howlader, N., Noone, A.M., Krapcho, M., Garshell, J., Neyman, N., 
Altekruse, S.F., Kosary, C.L., Yu, M., Ruhl, J., Tatalovich, Z. et al. SEER 
Cancer Statistics Review 1975 – 2010. National Cancer Institute, Bethesda, 
MD, USA. 
4.  Aben, K.K.H., Witjes, J.A., Schoenberg, M.P., Hulsbergen-van de Kaa, C., 
Verbeek, A.L.M. and Kiemeney, L.A.L.M. (2002) Familial aggregation of 
urothelial cell carcinoma. Int. J. Cancer J. Int. Cancer, 98, 274 – 278. 
5.  Murta-Nascimento, C., Silverman, D.T., Kogevinas, M., Garcı´a-Closas, M., 
Rothman, N., Tardo´ n, A., Garcı´a-Closas, R., Serra, C., Carrato, A., 
Villanueva, C. et al. (2007) Risk of bladder cancer associated with family 
history of cancer: do low-penetrance polymorphisms account for the 
increase in risk? Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer 
Res. Cosponsored Am. Soc. Prev. Oncol., 16, 1595 – 1600. 
6.  Dong, C. and Hemminki, K. (2001) Modification of cancer risks in offspring 
by sibling and parental cancers from 2,112,616 nuclear families. 
Int. J. Cancer J. Int. Cancer, 92, 144 – 150. 
7.  Aben, K.K.H., Baglietto, L., Baffoe-Bonnie, A., Coebergh, J.-W.W., 
Bailey-Wilson, J.E., Trink, B., Verbeek, A.L.M., Schoenberg, M.P., Alfred 
Witjes, J. and Kiemeney, L.A. (2006) Segregation analysis of urothelial cell 
carcinoma. Eur. J. Cancer Oxf. Engl., 42, 1428 – 1433. 
8.  Garcı´a-Closas, M., Malats, N., Silverman, D., Dosemeci, M., Kogevinas, M., 
Hein, D.W., Tardo´ n, A., Serra, C., Carrato, A., Garcı´a-Closas, R. et al. (2005) 
NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: 
results from the Spanish Bladder Cancer Study and meta-analyses. Lancet, 
366, 649 – 659. 
9.  Kiemeney, L.A., Thorlacius, S., Sulem, P., Geller, F., Aben, K.K.H., Stacey, 
S.N., Gudmundsson, J., Jakobsdottir, M., Bergthorsson, J.T., Sigurdsson, A. 
et al. (2008) Sequence variant on 8q24 confers susceptibility to urinary 
bladder cancer. Nat. Genet., 40, 1307 – 1312. 
10. Wu, X., Ye, Y., Kiemeney, L.A., Sulem, P., Rafnar, T., Matullo, G., 
Seminara, D., Yoshida, T., Saeki, N., Andrew, A.S. et al. (2009) Genetic 
variation in the prostate stem cell antigen gene PSCA confers susceptibility 
to urinary bladder cancer. Nat. Genet., 41, 991 – 995. 
11. Kiemeney, L.A., Sulem, P., Besenbacher, S., Vermeulen, S.H., Sigurdsson, 
A., Thorleifsson, G., Gudbjartsson, D.F., Stacey, S.N., Gudmundsson, J., 
Zanon, C. et al. (2010) A sequence variant at 4p16.3 confers susceptibility to 
urinary bladder cancer. Nat. Genet., 42, 415 – 419. 
12. Rothman, N., Garcia-Closas, M., Chatterjee, N., Malats, N., Wu, X., 
Figueroa, J.D., Real, F.X., Van Den Berg, D., Matullo, G., Baris, D. et al. 
(2010) A multi-stage genome-wide association study of bladder cancer 
identifies multiple susceptibility loci. Nat. Genet., 42, 978 – 984. 
13. Rafnar, T., Vermeulen, S.H., Sulem, P., Thorleifsson, G., Aben, K.K., 
Witjes, J.A., Grotenhuis, A.J., Verhaegh, G.W., Hulsbergen-van de Kaa, 
C.A., Besenbacher, S. et al. (2011) European genome-wide association study 
identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. 
Hum. Mol. Genet., 20, 4268 – 4281. 
14. Garcia-Closas, M., Ye, Y., Rothman, N., Figueroa, J.D., Malats, N., Dinney, 
C.P., Chatterjee, N., Prokunina-Olsson, L., Wang, Z., Lin, J. et al. (2011) A 
genome-wide association study of bladder cancer identifies a new 
susceptibility locus within SLC14A1, a urea transporter gene on 
chromosome 18q12.3. Hum. Mol. Genet., 20, 4282 – 4289. 
15. Figueroa, J.D., Ye, Y., Siddiq, A., Garcia-Closas, M., Chatterjee, N., 
Prokunina-Olsson, L., Cortessis, V.K., Kooperberg, C., Cussenot, O., 
Benhamou, S. et al. (2013) Genome-wide association study identifies 
multiple loci associated with bladder cancer risk. Hum. Mol. Genet., 23, 
1387 – 1398. doi:10.1093/hmg/ddt519. 
16. Kong, A., Masson, G., Frigge, M.L., Gylfason, A., Zusmanovich, P., 
Thorleifsson, G., Olason, P.I., Ingason, A., Steinberg, S., Rafnar, T. et al. 
(2008) Detection of sharing by descent, long-range phasing and haplotype 
imputation. Nat. Genet., 40, 1068 – 1075. 
17. Kong, A., Steinthorsdottir, V., Masson, G., Thorleifsson, G., Sulem, P., 
Besenbacher, S., Jonasdottir, A., Sigurdsson, A., Kristinsson, K.T., 
Jonasdottir, A. et al. (2009) Parental origin of sequence variants associated 
with complex diseases. Nature, 462, 868 – 874. 
18. Styrkarsdottir, U., Thorleifsson, G., Sulem, P., Gudbjartsson, D.F., 
Sigurdsson, A., Jonasdottir, A., Jonasdottir, A., Oddsson, A., Helgason, A., 
Magnusson, O.T. et al. (2013) Nonsense mutation in the LGR4 gene is 
associated with several human diseases and other traits. Nature, 497, 
517 – 520. 
19. Kong, A., Thorleifsson, G., Gudbjartsson, D.F., Masson, G., Sigurdsson, A., 
Jonasdottir, A., Walters, G.B., Jonasdottir, A., Gylfason, A., Kristinsson, 
K.T. et al. (2010) Fine-scale recombination rate differences between sexes, 
populations and individuals. Nature, 467, 1099 – 1103. 
20. Pruim, R.J., Welch, R.P., Sanna, S., Teslovich, T.M., Chines, P.S., Gliedt, 
T.P., Boehnke, M., Abecasis, G.R. and Willer, C.J. (2010) LocusZoom: 
regional visualization of genome-wide association scan results. 
Bioinformatics, 26, 2336 – 2337. 
21. Knowles, M.A. (2006) Molecular subtypes of bladder cancer: Jekyll and 
Hyde or chalk and cheese? Carcinogenesis, 27, 361 – 373. 
22. Lobry, C., Oh, P. and Aifantis, I. (2011) Oncogenic and tumor suppressor 
functions of Notch in cancer: it’s NOTCH what you think. J. Exp. Med., 208, 
1931 – 1935. 
23. Shi, T., Xu, H., Wei, J., Ai, X., Ma, X., Wang, B., Ju, Z., Zhang, G., Wang, C., 
Wu, Z. et al. (2008) Association of low expression of notch-1 and jagged-1 in 
human papillary bladder cancer and shorter survival. J. Urol., 180, 361 – 366. 
24. Vallot, C., Stransky, N., Bernard-Pierrot, I., He´rault, A., Zucman-Rossi, J., 
Chapeaublanc, E., Vordos, D., Laplanche, A., Benhamou, S., Lebret, T. et al. 
(2011) A novel epigenetic phenotype associated with the most aggressive 
pathway of bladder tumor progression. J. Natl. Cancer Inst., 103, 47 – 60. 
25. Rosenbloom, K.R., Sloan, C.A., Malladi, V.S., Dreszer, T.R., Learned, K., 
Kirkup, V.M., Wong, M.C., Maddren, M., Fang, R., Heitner, S.G. et al. 
(2013) ENCODE data in the UCSC Genome Browser: year 5 update. Nucleic 
Acids Res., 41, D56 – D63. 
26. Meyer, L.R., Zweig, A.S., Hinrichs, A.S., Karolchik, D., Kuhn, R.M., Wong, 
M., Sloan, C.A., Rosenbloom, K.R., Roe, G., Rhead, B. et al. (2013) The 
UCSC Genome Browser database: extensions and updates 2013. Nucleic 
Acids Res., 41, D64 – D69. 
27. Ward, L.D. and Kellis, M. (2012) HaploReg: a resource for exploring 
chromatin states, conservation, and regulatory motif alterations within sets 
of genetically linked variants. Nucleic Acids Res., 40, D930 – D934. 
28. Boyle, A.P., Hong, E.L., Hariharan, M., Cheng, Y., Schaub, M.A., 
Kasowski, M., Karczewski, K.J., Park, J., Hitz, B.C., Weng, S. et al. (2012) 
Annotation of functional variation in personal genomes using RegulomeDB. 
Genome Res., 22, 1790 – 1797. 
29. Ng, S.B., Turner, E.H., Robertson, P.D., Flygare, S.D., Bigham, A.W., Lee, 
C., Shaffer, T., Wong, M., Bhattacharjee, A., Eichler, E.E. et al. (2009)
5558  5558  
 
 
 
Targeted capture and massively parallel sequencing of 12 human exomes. 
Nature, 461, 272 – 276. 
30. Kung, A.W.C., Xiao, S.-M., Cherny, S., Li, G.H.Y., Gao, Y., Tso, G., Lau, 
K.S., Luk, K.D.K., Liu, J., Cui, B. et al. (2010) Association of JAG1 with 
bone mineral density and osteoporotic fractures: a genome-wide association 
study and follow-up replication studies. Am. J. Hum. Genet., 86, 229 – 239. 
31. Estrada, K., Styrkarsdottir, U., Evangelou, E., Hsu, Y.-H., Duncan, E.L., 
Ntzani, E.E., Oei, L., Albagha, O.M.E., Amin, N., Kemp, J.P. et al. (2012) 
Genome-wide meta-analysis identifies 56 bone mineral density loci and 
reveals 14 loci associated with risk of fracture. Nat. Genet., 44, 491 – 501. 
32. International Consortium for Blood Pressure Genome-Wide Association 
Studies, Ehret, G.B., Munroe, P.B., Rice, K.M., Bochud, M., Johnson, A.D., 
Chasman, D.I., Smith, A.V., Tobin, M.D., Verwoert, G.C. et al. (2011) 
Genetic variants in novel pathways influence blood pressure and 
cardiovascular disease risk. Nature, 478, 103 – 109. 
33. Espinoza, I. and Miele, L. (2013) Notch inhibitors for cancer treatment. 
Pharmacol. Ther., 139, 95 – 110. 
34. Lukk, M., Kapushesky, M., Nikkila¨, J., Parkinson, H., Goncalves, A., Huber, 
W., Ukkonen, E. and Brazma, A. (2010) A global map of human gene 
expression. Nat. Biotechnol., 28, 322 – 324. 
35. The Cancer Genome Atlas Research Network. (2014) Comprehensive 
molecular characterization of urothelial bladder carcinoma. Nature, 507, 
315 – 322. doi:10.1038/nature12965. 
36. Hirao, S., Hirao, T., Marsit, C.J., Hirao, Y., Schned, A., Devi-Ashok, T., 
Nelson, H.H., Andrew, A., Karagas, M.R. and Kelsey, K.T. (2005) Loss of 
heterozygosity on chromosome 9q and p53 alterations in human bladder 
cancer. Cancer, 104, 1918 – 1923. 
37. Wetzels, J.F.M., Kiemeney, L.A.L.M., Swinkels, D.W., Willems, H.L. and 
den Heijer, M. (2007) Age- and gender-specific reference values of 
estimated GFR in Caucasians: the Nijmegen Biomedical Study. Kidney Int., 
72, 632 – 637. 
38. Sak, S.C., Barrett, J.H., Paul, A.B., Bishop, D.T. and Kiltie, A.E. (2005) The 
polyAT, intronic IVS11 – 6 and Lys939Gln XPC polymorphisms are not 
associated with transitional cell carcinoma of the bladder. Br. J. Cancer, 92, 
2262 – 2265. 
39. Matullo, G., Guarrera, S., Sacerdote, C., Polidoro, S., Davico, L., Gamberini, 
S., Karagas, M., Casetta, G., Rolle, L., Piazza, A. et al. (2005) 
Polymorphisms/haplotypes in DNA repair genes and smoking: a bladder 
cancer case-control study. Cancer Epidemiol. Biomark. Prev. Publ. Am. 
Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol., 14, 2569 – 2578. 
40. Shen, M., Hung, R.J., Brennan, P., Malaveille, C., Donato, F., Placidi, D., 
Carta, A., Hautefeuille, A., Boffetta, P. and Porru, S. (2003) Polymorphisms 
of the DNA repair genes XRCC1, XRCC3, XPD, interaction with 
environmental exposures, and bladder cancer risk in a case-control study in 
northern Italy. Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer 
Res. Cosponsored Am. Soc. Prev. Oncol., 12, 1234 – 1240. 
41. Kellen, E., Zeegers, M., Paulussen, A., Van Dongen, M. and Buntinx, F. 
(2006) Fruit consumption reduces the effect of smoking on bladder cancer 
risk. The Belgian case control study on bladder cancer. Int. J. Cancer, 118, 
2572 – 2578. 
42. Thirumaran, R.K., Bermejo, J.L., Rudnai, P., Gurzau, E., Koppova, K., 
Goessler, W., Vahter, M., Leonardi, G.S., Clemens, F., Fletcher, T. et al. 
(2006) Single nucleotide polymorphisms in DNA repair genes and basal cell 
carcinoma of skin. Carcinogenesis, 27, 1676 – 1681. 
43. Larsson, P., Wijkstro¨ m, H., Thorstenson, A., Adolfsson, J., Norming, U., 
Wiklund, P., Onelo¨ v, E. and Steineck, G. (2003) A population-based study of 
538 patients with newly detected urinary bladder neoplasms followed during 
5 years. Scand. J. Urol. Nephrol., 37, 195 – 201. 
44. Lehmann, M.-L., Selinski, S., Blaszkewicz, M., Orlich, M., Ovsiannikov, D., 
Moormann, O., Guballa, C., Kress, A., Truss, M.C., Gerullis, H. et al. (2010) 
Rs710521[A] on chromosome 3q28 close to TP63 is associated with 
increased urinary bladder cancer risk. Arch. Toxicol., 84, 967 – 978. 
45. Golka, K., Schmidt, T., Seidel, T., Dietrich, H., Roemer, H.C., Lohlein, D., 
Reckwitz, T., Sokeland, J., Weistenhofer, W., Blaszkewicz, M. et al. (2008) 
The influence of polymorphisms of glutathione S-transferases M1 and M3 on 
the development of human urothelial cancer. J. Toxicol. Environ. Health A, 
71, 881 – 886. 
46. Golka, K., Hermes, M., Selinski, S., Blaszkewicz, M., Bolt, H.M., Roth, G., 
Dietrich, H., Prager, H.-M., Ickstadt, K. and Hengstler, J.G. (2009) 
Susceptibility to urinary bladder cancer: relevance of rs9642880[T], 
GSTM1 0/0 and occupational exposure. Pharmacogenet. Genomics, 19, 
903 – 906. 
47. Howie, B.N., Donnelly, P. and Marchini, J. (2009) A flexible and accurate 
genotype imputation method for the next generation of genome-wide 
association studies. PLoS Genet., 5, e1000529. 
48. Marchini, J., Howie, B., Myers, S., McVean, G. and Donnelly, P. (2007) A 
new multipoint method for genome-wide association studies by imputation 
of genotypes. Nat. Genet., 39, 906 – 913. 
49. Kutyavin, I.V., Milesi, D., Belousov, Y., Podyminogin, M., Vorobiev, A., 
Gorn, V., Lukhtanov, E.A., Vermeulen, N.M.J. and Mahoney, W. (2006) A 
novel endonuclease IV post-PCR genotyping system. Nucleic Acids Res., 
34, e128. 
50. Kong, A., Gudbjartsson, D.F., Sainz, J., Jonsdottir, G.M., Gudjonsson, S.A., 
Richardsson, B., Sigurdardottir, S., Barnard, J., Hallbeck, B., Masson, G. 
et al. (2002) A high-resolution recombination map of the human genome. 
Nat. Genet., 31, 241 – 247. 
51. Gretarsdottir, S., Thorleifsson, G., Reynisdottir, S.T., Manolescu, A., 
Jonsdottir, S., Jonsdottir, T., Gudmundsdottir, T., Bjarnadottir, S.M., 
Einarsson, O.B., Gudjonsdottir, H.M. et al. (2003) The gene encoding 
phosphodiesterase 4D confers risk of ischemic stroke. Nat. Genet., 35, 
131 – 138. 
52. Mantel, N. and Haenszel, W. (1959) Statistical aspects of the analysis of data 
from retrospective studies of disease. J. Natl. Cancer Inst., 22, 719 – 748. 
53. Higgins, J.P.T. and Thompson, S.G. (2002) Quantifying heterogeneity in a 
meta-analysis. Stat. Med., 21, 1539 – 1558. 
54. Kapushesky, M., Adamusiak, T., Burdett, T., Culhane, A., Farne, A., 
Filippov, A., Holloway, E., Klebanov, A., Kryvych, N., Kurbatova, N. et al. 
(2012) Gene Expression Atlas update – a value-added database of 
microarray and sequencing-based functional genomics experiments. 
Nucleic Acids Res., 40, D1077 – D1081. 
55. El Behi, M., Krumeich, S., Lodillinsky, C., Kamoun, A., Tibaldi, L., Sugano, 
G., De Reynies, A., Chapeaublanc, E., Laplanche, A., Lebret, T. et al. (2013) 
An essential role for decorin in bladder cancer invasiveness. EMBO Mol. 
Med., 5, 1835 – 1851. doi:10.1002/emmm.201302655. 
56. Morgan, R., Bryan, R.T., Javed, S., Launchbury, F., Zeegers, M.P., Cheng, 
K.K., James, N.D., Wallace, D.M.A., Hurst, C.D., Ward, D.G. et al. (2013) 
Expression of Engrailed-2 (EN2) protein in bladder cancer and its potential 
utility as a urinary diagnostic biomarker. Eur. J. Cancer Oxf. Engl., 49, 
2214 – 2222. doi:10.1016/j.ejca.2013.01.019. 
57. Southgate, J., Hutton, K.A., Thomas, D.F. and Trejdosiewicz, L.K. (1994) 
Normal human urothelial cells in vitro: proliferation and induction of 
stratification. Lab. Investig. J. Tech. Methods Pathol., 71, 583 – 594. 
